News stories about China Biologic Products (NASDAQ:CBPO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. China Biologic Products earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.0597400886958 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of NASDAQ CBPO opened at $86.84 on Wednesday. The stock has a market capitalization of $2,809.00, a PE ratio of 17.54, a price-to-earnings-growth ratio of 1.29 and a beta of 1.45. China Biologic Products has a 52 week low of $71.85 and a 52 week high of $120.46.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.01. The business had revenue of $90.10 million during the quarter, compared to analysts’ expectations of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The company’s quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.95 earnings per share. sell-side analysts anticipate that China Biologic Products will post 5.22 EPS for the current fiscal year.
A number of equities analysts have weighed in on CBPO shares. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Jefferies Group restated a “buy” rating and set a $97.00 price objective on shares of China Biologic Products in a research report on Thursday, March 15th. Deutsche Bank set a $105.00 target price on shares of China Biologic Products and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, TheStreet cut shares of China Biologic Products from a “b-” rating to a “c+” rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $101.00.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/11/china-biologic-products-cbpo-receiving-somewhat-favorable-media-coverage-study-shows.html.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.